Prosensa is a biotechnology company engaged in the discovery, development and commercialization of RNA-modulating therapeutics . The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy and Huntington's disease.

Publications show all

Prosensa has published 12 articles.

Patents show all

104Applications42Issued

Clinical Trials show all

1Phase 1/Phase 2

SEC Filings show all

D1

Private Funding Events

DateOfferedSoldType
2014-12-08$50,488,095$50,488,095Debt, Option to Acquire

Contact Information

    Key Executives

    • Hans Schikan
      Executive Officer
    • Giles Campion
      Executive Officer
    • Berndt Modig
      Executive Officer
    • Luc Dochez
      Executive Officer
    • Peter Goodfellow
      Director
    • David Mott
      Director
    • Daan Ellens
      Director
    • Martijn Kleijwegt
      Director
    • Annalisa Jenkins
      Director
    • Michael Wyzga
      Director
    • Georges Gemayel
      Director